SEC Company Response from Can-Fite BioPharma Ltd. (CANF) (CIK 0001536196) (CANF) — Jun 12, 2017
Can-Fite BioPharma Ltd. (CANF) (CIK 0001536196)
Date: June 12, 2017 · CIK: 0001536196 · Accession: 0001213900-17-006355
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-218336
Letter
CAN-FITE BIOPHARMA LTD.
10 Bareket Street,
Kiryat Matalon
PO Box 7537
Petach Tikva, 4951778
Israel
June 12, 2017
VIA EDGAR
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Chris Edwards
Re: Can-Fite BioPharma Ltd.
Registration Statement on Form F-1 Filed May 30, 2017
File No. 333-218336
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Can-Fite BioPharma Ltd. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:00 p.m., Eastern Time, on June 13, 2017, or as soon thereafter as possible.
The Company hereby acknowledges the following:
· should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
· the Company may not assert staff comments and the declaration of effectiveness of this Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
CAN-FITE BIOPHARMA LTD.
By: /s/ Pnina Fishman
Name: Pnina Fishman
Title: Chief Executive Officer
Show Raw Text
CORRESP
1
filename1.htm
CAN-FITE BIOPHARMA LTD.
10 Bareket Street,
Kiryat Matalon
PO Box 7537
Petach Tikva, 4951778
Israel
June 12, 2017
VIA EDGAR
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Chris Edwards
Re:
Can-Fite BioPharma Ltd.
Registration Statement on Form F-1 Filed May 30, 2017
File No. 333-218336
Ladies and Gentlemen:
Pursuant to Rule 461 of
the General Rules and Regulations under the Securities Act of 1933, as amended, Can-Fite BioPharma Ltd. (the “Company”)
respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become
effective at 4:00 p.m., Eastern Time, on June 13, 2017, or as soon thereafter as possible.
The Company hereby acknowledges
the following:
·
should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
·
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
·
the Company may not assert staff comments and the declaration of effectiveness of this Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
CAN-FITE BIOPHARMA LTD.
By:
/s/ Pnina Fishman
Name:
Pnina Fishman
Title:
Chief Executive Officer